Trial Profile
The hypertensive patients is RECOMMENDed for organ protection by ARB decreased early-morning blood pressure study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 Aug 2015
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary) ; Olmesartan medoxomil (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms RECOMMEND
- 24 Jul 2013 New trial record